Elan Corp PLC (ELN)

[HAK41]

Link for today's PR Release is located in I-Box.
Geared up a bit slow today, but at least it was in the right direction.

[gemstone57]

Just what the Doctor ordered

[HAK41]

Press Release is out as of 2:00 AM ET ( 7:00 AM Dublin Time ), relative to a merger of Alkermes and the Elan Technology Unit, forming a new entity called Alkermes plc, headquartered in Dublin.
The transaction of $ 960 million will throw approximately $ 500 million in cash plus Alkermes shares into Elan's coffers.
The merger should be finalized later this year..........
could be an interesting day for ELN shares today.
:)

[HAK41]

Maybe you need to reread my comment. I referred to the type of application used. I am fully aware of the difference in drugs and their purpose. Perhaps, I needed to make it even more clearer for some folks who might be linguistically challenged.
You have to excuse me, English is my third language.

[DewDiligence]

Since BG-12 could cut into future sales of all present MS drugs including Elan's, they need to hope that it works better than Pfizer's attempt at taking the oral route of administering the drug.

You’re mixing up two stories. PFE’s oral drug mentioned in the article you posted is for RA , not MS.

[HAK41]

http://www.marketwatch.com/story/biogen-shares-surge-after-ms-drug-study-2011-04-21?siteid=yhoof
Interesting brief article and comments re: Biogen's BG-12 Phase 3 trials.
Since BG-12 could cut into future sales of all present MS drugs including Elan's, they need to hope that it works better than Pfizer's attempt at taking the oral route of administering the drug.

[HAK41]

1st Qtr Results: most abbreviated version -
.01 loss, but beats Thomson Reuters consensus by .02
Revs : 310.5 million vs. 297 million consensus.

[DewDiligence]

Tysabri 1Q11 in-market sales: $170M US, $180M ex-US, $349M total:

http://finance.yahoo.com/news/Elan-Reports-First-Quarter-bw-3397570445.html

Comparison to Copaxone in US market: #msg-62261258.

[gemstone57]

Nice to see some action here!!!

[HAK41]

Reminder :
1st Quarter Earnings Conference Call is scheduled for 8:30 AM ET tomorrow April 20th.

[io_io]

masterlongevity

After the magnificent recent successes of Elan spinoffs ACOR and especially that mutli-multi-bagger AMRN - http://investorshub.advfn.com/boards/board.aspx?board_id=8662 - and one further spinoff yet to come, a "player to be named later" -

- the question beckons, isnt it time for Elan itself .......

[HAK41]

It's somewhat sad that everyone seems to have disappeared from this board, since just in this last month ELN seems to be on a resurrection path with a small 25 % plus increase in PPS while most equities are doing the two shoe sidestep.
Considering Tysabri sales are still increasing with additional better news forthcoming in other areas, perhaps the leprechauns are reheating their pot o' gold.

[DewDiligence]

BIIB reports two more cases of Tysabri PML (#69 and #70 overall):

#msg-55803073

20% of the 70 confirmed PML cases have been fatal.

For patients who have been on therapy for at least two years, the PML incidence has been 1 case in every 535 patients.

[deet49]

P3 clinical trials now the leader in the race for alzimers treatment

Dr. Daniel Chain, is the inventor and patent holder for the technology platform on which most of the leading drug candidates (most visibily Bapineuzumab)
http://biomedreports.com/articles/most-popular/51039-exclusive-numerous-false-starts-by-others-dont-discourage-this-companys-search-for-alzheimers-treatment.html

Narration:

Alzheimer's affects over 30 million people worldwide.

That number is expected to double in the next 30 years.

"Early-onset" Alzheimer's can affect people as young as 40.

Dr. Chain:

We believe that the root cause for Alzheimer's disease is the accumulation of a protein known as beta-amyloid in the brain of Alzheimer's patients.


http://www.alzheimersweekly.com/Research/how-vaccines-clear-alzheimers-plaque-a800.html

[DewDiligence]

Copaxone Continues Cleaning Tysabri’s Clock in US Market:

#msg-52673284

[DewDiligence]

Yet another large shareholder demands cleanup of ELN management/BoD:

#msg-52554549

[mr10001]

Double Bottom?

Fooled me again

[DewDiligence]

FDA advisory panel voted 25-0 in favor of Gilenia on both efficacy and safety.

[DewDiligence]

Gilenia briefing docs and draft questions for the advisory panel:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51021684
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51021749

[mr10001]

Bottomed Out?

I think this is the turn.

bought in at 5.7

[dragonball]

<Proof once again that prejudice and pumping do not make for good investment fundamentals.
>

I agree with this statement!

I better go do more Due Deligence!

Good luck all!

[io_io]

Dew - <" A few more days like today and it could actually happen ">

Well in those exact "few more days" I see that it is not ELN, but MNTA and IDIX which both have lost almost 25% of their values:

http://moneycentral.msn.com/investor/charts/chartdl.aspx?compsyms=mnta%2c+idix&D4=1&DD=1&D5=0&DCS=2&MA0=0&MA1=0&C5=5&C5D=6&C6=2010&C7=5&C7D=8&C8=2010&C9=-1&CF=0&showchartbt=Redraw+chart&symbol=eln&nocookie=1&SZ=0&CP=0&PT=1

This plunge repeats the pattern of a previous hate-post on ELN -

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=44712572

Proof once again that prejudice and pumping do not make for good investment fundamentals.

[DewDiligence]

…$4 price target

A few more days like today and it could actually happen. P.S. Thanks for your PM.

[DewDiligence]

How much value are they ascribing to the EDT business?

[surf1944]

Elan ELN Brean Murray started today with a Sell & $4 price target

[io_io]

<" After reading the transcript, it is clear that kelyl martin doesn't know anything about science or drug devlopment and shouldnt be talking publicly about the pipeline. ">

Well I would be worried if they made him CMO. I neither like or dislike him, but I recall Adam F's hatchet job on him was devoid of a single quotation - because as far as I could tell, he said nothing wrong. He was NOT the first to say "absolutely spectacular" - that was the Wyeth guys - and that was in the context of moving Bapi to p3 on the basis of the p2 first look - which was not only an "IF", it actually did NOT happen upon that look. But it lived on in message boards, and I guess Adam F reads such boards.

Anyway, this MDVN failure throws open the Alz race, or perhaps closes it as a one-horse race. I am back into Elan, intending to own it without ever having to look at the imploded mood of the IV board. I suppose "never" is impossible, but its a no-brainer, they simply have too many shots on goal, or rather, canons on goal.

Plus it has 50% the valuation of VRTX, and similar to OSIP. Really the Alz program comes for free. In fact I think even the ACOR royalties come for free !

[masterlongevity]

i had a different takeaway from cowen meeting. After reading the transcript, it is clear that kelyl martin doesn't know anything about science or drug devlopment and shouldnt be talking publicly about the pipeline.

in explaining the differences between drugs in the pipeline, he said "They are all slightly different from a PK point of view. "

end of explanation. great job!

[io_io]

<" still skeptical about clinical endpoints ">

Its the same for almost every p3 trial program. There was enough evidecne to take it forward to p3, despite in fact a small trial size.

I am just watching the Cowen show, and the stock seems incredinly under-valued.

[masterlongevity]

i thought the pet-pib data was great. still skeptical about clinical endpoints, but holding out hope

[io_io]

<" i agree with you. i think the lights are out, not jsut dim ">


Actually it makes the Elan data look distinctly better now. Those little cohorts that everyone bashed. Still a year away I guess, but I am thinking.

[masterlongevity]

i agree with you. i think the lights are out, not jsut dim

[io_io]

The lights go Dim on Dimebon - masterlongevity

http://finance.yahoo.com/news/Pfizer-And-Medivation-bw-1529603404.html?x=0&.v=1

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47105067

The science and research background was never in its favor.

And this wont happen either - trust me:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=47312994

[lightbeam]

Thats like me. LOL I caught it as they hit the news. First day I had news on in long time! Most I do not listen to.

[fourkids_9pets]

it's funny after 15 years of listening
i've learned to tune out 95 percent of it

and just snag the goodies as they come thru

i just couldn't believe the timing of this one

that is a rarity for sure

--
4kids
all jmo

[lightbeam]

Had to laugh at that today. They were so down on everyting today. Sounds like shorters to me all day. Good thing I play the pennies. God they are complainers on big boards .They sure picked up on that news.

[fourkids_9pets]

hey lightbeam ..

life is good .. hope all
is well with you

yep i always have cnbc on
in the background and sometimes
it pays off .. :)

--
4kids
all jmo

[lightbeam]

How ya doing? Watching ah!

[fourkids_9pets]

very nice 5 minute window given
just before market closed .. courtesy
of cnbc's mike huckman

excellent timing .. :)

--
FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis

By: PR Newswire | 22 Jan 2010 | 03:37 PM ET Text Size

SILVER SPRING, Md., Jan 22, 2010 /PRNewswire via COMTEX/ -- The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO) MS is a chronic, often disabling, disease that affects the central nervous system--the brain, spinal cord, and optic nerves. There are about 400,000 people in the United States and 2.5 million people world-wide with MS.

The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. Symptoms can be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. About half of all people with MS experience cognitive impairments like difficulties in concentration, attention, memory, and judgment, although these symptoms are usually mild and are frequently overlooked. Depression also is common among MS patients.

"Trouble with walking is one of the most debilitating problems people with MS face," said Russell Katz, M.D., director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research.

Ampyra, when given at doses greater than that recommended (10 milligrams twice a day), can cause seizures. The most common adverse reactions reported by patients taking Ampyra in clinical trials include urinary tract infection, insomnia, dizziness, headache, nausea, weakness, back pain, balance disorder, swelling in the nose or throat, constipation, diarrhea, indigestion, throat pain, and burning, tingling or itching of skin.

Ampyra should not be used in patients with moderate to severe kidney disease. In these patients, blood levels with the drug approach those associated with the occurrence of seizures.

Ampyra will be manufactured under licenses from Elan of Dublin, Ireland, and distributed by Acorda Therapeutics Inc. of Hawthorne, N.Y.

For information about FDA drug approvals: http://www.fda.gov/Drugs/default.htm.

Contact: Sandy Walsh, 301-796-4669, [e-mail] SOURCE U.S. Food and Drug Administration www.prnewswire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Maryland INDUSTRY KEYWORD: HEA

MTC

PHA SUBJECT CODE: POL

FDA

EXE

TRI

---
4kids
all jmo

[io_io]

<" ELN must be the worst large-cap biotech stock in the history of the world ">

- dated October 23rd, 2009 - so you say DewD, an extraordinary statement.

But that same week, could you have considered that IDIX might make ELN (which after all, does have a $1bn blockbuster drug) look a god-sent salvation from yet another downward spiral into a bottomles sink-hole ?

http://finance.yahoo.com/q/hp?s=IDIX&a=09&b=22&c=2009&d=10&e=10&f=2009&g=d

[kei]

glad that i took all my profit at the price above $8.00 !
since then never came back... many thanks to io_io for the timely advice!

[DewDiligence]

ELN must be the worst large-cap biotech stock in the history of the world.

[DewDiligence]

NVS Reports Positive FTY720 FREEDOMS Data in RRMS:

#msg-42018880

[MacTheKnife]

>> With a $3m valuation, and an ARR benefit in the
>> MS trial like that, this one is going all the way
>> back to where it fell from. I loaded up @ 22c and
>> 19c .........


>> just give this one 6 months, or whatever the gestation
>> period of a goat is..........

It seems like the gestation period of a goat has fallen to less than a month. Nice call.

Once again Dew shows himself to be a wonderful contrarian indicator.

[io_io]

masterlongevity re: PML & OPXA

You have always posted knowledgably about MS, and I remember years ago having to consistently correct your assertions that Rituxan was going to succeed first in RRMS and later in PPMS.

So instead of your constant gratuituous self-congratulations every time a PMl case comes up, why didnt you latch on to my posts on OPXA's Tovaxin data ?

Look at this, OPXA is now a 50-bagger after hitting $7 yesterday.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=40461598

And what is more, you are wasting your time with Tysabri, it will persevere despite your and Dew's irrelevant contempt for all-things Elan.

[DewDiligence]

ELN Breached Tysabri Agreement with BIIB

[Several posters on this board have cited the ineptness of ELN’s CEO. Evidently, ELN’s legal staff has some shortcomings too.]

#msg-41177920

[EDWARD STEVENSON]

Video chart 08.19.09

Closing Wednesday's trading session at $7.14, the price is situated on critical support. Resistance awaits the price at the 10MA ($7.46) and 50MA ($7.43), respectfully. My thoughts and analysis in video format follow.

Link to video chart: http://timelesswealth.net/eln.html

[MacTheKnife]

>> With a $3m valuation, and an ARR benefit in the
>> MS trial like that, this one is going all the way
>> back to where it fell from. I loaded up @ 22c and
>> 19c .........just give this one 6 months, or
>> whatever the gestation period of a goat is..........

io - you were wrong. It took 9 months and not 6. And the gestation period of a goat is 5-6 months. So even tho the stock did indeed to right back to where it came from - I have to say you were wrong

[io_io]

Zebra’s Law? or is it a Goat?

Thank Dew for bringing OPXA to my attention in this post !!

Posting and doing real DD on Elan gives one expertise in MS, especially ARR numbers, and this is what I advised you in my two previous replies -

"That ARR looks very good. It is absolutely essential that a Phase III be done."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=32310307


"with an ARR benefit in the MS trial like that, this one is going all the way back to where it fell from.... I loaded up @ 22c and 19c"

http://investorshub.advfn.com/boards/replies.aspx?msg=32302329

Well on Friday this one ripped to almost $3 (yep a 15-bagger) - and that is without even any announcement of a new MS trial. Instead - outstanding science gets rewarded -

http://investorshub.advfn.com/boards/board.aspx?board_id=8741

Today it has pulled back somewhat - just wait for the MS trial, in time.

So Dew tell us what Zebra's Law means again? Is it about biotech science?

[blackcat]

Elan Files Declaratory Suit Against Biogen Idec

Elan Corporation PLC


Elan Files Declaratory Suit Against Biogen Idec;

Company Has Not Breached Tysabri® Collaboration Agreement

Elan Corporation, plc (ISE:ELA) today announced that it has filed suit against Biogen Idec Inc. in Federal Court in New York seeking declaratory and injunctive relief that certain aspects of Elan’s recently announced transaction with affiliates of Johnson & Johnson (the “Transaction”) comply with Elan’s Collaboration Agreement with Biogen Idec for the development and marketing of Tysabri (the “Collaboration Agreement”).

In a letter to Elan dated July 28, 2009, Biogen Idec alleged that Elan was in material breach of the Collaboration Agreement. Biogen Idec’s assertion against Elan relates to Elan’s ability to obtain financing from an affiliate of Johnson & Johnson to potentially purchase Biogen Idec’s Tysabri rights, if Biogen Idec undergoes a change of control. Biogen Idec made this assertion even though it was not in possession of the relevant agreement related to the Transaction at the time, which Elan has offered to share with Biogen Idec. Elan strongly believes that it is in compliance in all respects with the Collaboration Agreement.

Elan is committed to aggressively and proactively protecting its science, property and assets.

Elan noted in a statement, “There's nothing in the pending Transaction that is contrary to our collaboration agreement with Biogen Idec for Tysabri, an important therapeutic discovered and primarily developed by Elan. Elan’s collaboration with Biogen Idec has been in place since 2000. During that time, Elan and Biogen Idec have obtained regulatory approval for Tysabri in the United States, the European Union and other countries and have made the significant benefits of Tysabri available to a growing number of patients throughout these countries. Nothing about that relationship has changed. This is the same agreement we have been operating under for the last nine years. It is unfortunate that, because of Biogen Idec’s actions, Elan was left with no alternative but to seek court intervention to protect its interest.”

In seeking declaratory relief, Elan has requested that the Court conduct expedited proceedings given the sixty (60) day cure period following which Biogen may seek to terminate the Elan-Biogen Collaboration Agreement. Elan continues its previously stated commitment to closing the transaction with Johnson & Johnson as soon as possible.

Elan also requested that the Court enter judgment against Biogen Idec permanently enjoining Biogen Idec from terminating the Collaboration Agreement based on their July 28, 2009 Letter.

http://www.investegate.co.uk/article.aspx?id=20090806151500Z1477&fe=1

[kei]

thank you for the input, io_io :)
i may take my profit from eln next week.
thanks again :)